Payment overview · 2025
General Payments
$50.60
3 reported records · 3 companies
Healthcare provider profile · identity verified
Andrew Schlein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1861448946
Verified facts
What the public records show
CMS Open Payments records show Andrew Schlein, MD received $50.60 in general payments during 2025 across 3 reported records.
Philips North America LLC accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $19.14 | 37.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.04 | 31.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.42 | 30.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.60 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
80 | 76 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 461 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 87 |
| Alprazolam | Alprazolam | 296 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 269 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 238 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 66 |
| Losartan Potassium | Losartan Potassium | 214 | 61 |
| Gabapentin | Gabapentin | 175 | 46 |
| Trazodone Hcl | Trazodone Hcl | 150 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 46 |
| Potassium Chloride | Potassium Chloride | 141 | 40 |
| Temazepam | Temazepam | 134 | 31 |
| Eliquis | Apixaban | 128 | 32 |
| Metformin Hcl | Metformin Hcl | 121 | 34 |
| Omeprazole | Omeprazole | 115 | 35 |
| Ezetimibe | Ezetimibe | 102 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 33 |
| Allopurinol | Allopurinol | 96 | 27 |
| Azithromycin | Azithromycin | 93 | 65 |
| Simvastatin | Simvastatin | 90 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 23 |
| Ramipril | Ramipril | 83 | 22 |
| Paxlovid | Nirmatrelvir/Ritonavir | 80 | 76 |
| Ipratropium Bromide | Ipratropium Bromide | 77 | 25 |
| Sertraline Hcl | Sertraline Hcl | 77 | 23 |
| Ozempic | Semaglutide | 75 | 13 |
| Montelukast Sodium | Montelukast Sodium | 74 | 21 |
| Methylprednisolone | Methylprednisolone | 71 | 56 |
| Furosemide | Furosemide | 69 | 26 |
| Lisinopril | Lisinopril | 68 | 24 |
| Mirtazapine | Mirtazapine | 68 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 65 | 20 |
| Finasteride | Finasteride | 64 | 21 |
| Prednisone | Prednisone | 64 | 24 |
| Synthroid | Levothyroxine Sodium | 64 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 25 |
| Clonazepam | Clonazepam | 58 | 13 |
| Tramadol Hcl | Tramadol Hcl | 58 | 16 |
| Lorazepam | Lorazepam | 57 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 17 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 55 | suppressed |
| Famotidine | Famotidine | 53 | 19 |
| Spironolactone | Spironolactone | 52 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 20 |
| Xarelto | Rivaroxaban | 49 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 34 |
| Carvedilol | Carvedilol | 46 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 30 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Cephalexin | Cephalexin | 43 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 18 |
| Midodrine Hcl | Midodrine Hcl | 42 | 11 |
| Amoxicillin | Amoxicillin | 41 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 26 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Valsartan | Valsartan | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Praluent Pen | Alirocumab | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 13 |
| Risperidone | Risperidone | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Repaglinide | Repaglinide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.60 · 3 records | Philips North America LLC | Ambulatory Monitoring & Diagnostics Undivided, Ozempic, PAXLOVID, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error